Identification of Mycobacterium tuberculosis Resistance to Common Antibiotics: An Overview of Current Methods and Techniques

References

• Wang DM, Liu H, Zheng YL, Xu YH, Liao Y. Epidemiology of nontuberculous mycobacteria in tuberculosis suspects, Southwest of China, 2017–2022. Front Cell Infect Microbiol. 2023;13:1282902. doi:10.3389/fcimb.2023.1282902
   Web of Science ®Google Scholar
• Yu JJ, Tang SJ. 耐多药/利福平耐药结核病化学治疗年度进展2022 [Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022]. Zhonghua Jie He He Hu Xi Za Zhi. 2023;46(1):62–66. Chinese. doi:10.3760/cma.j.cn112147-20221030-00853
   Google Scholar
• Nusrath Unissa A, Hassan S, Indira Kumari V, Revathy R, Hanna LE. Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis. J Mol Graph Model. 2016;67:20–32. doi:10.1016/j.jmgm.2016.04.005
   Web of Science ®Google Scholar
• Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015;10(3):e0119628. doi:10.1371/journal.pone.0119628
   PubMed Web of Science ®Google Scholar
• Bifani P, Mathema B, Campo M, et al. Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain. Emerg Infect Dis. 2001;7(5):842–848. doi:10.3201/eid0705.010512
   Web of Science ®Google Scholar
• Spies FS, Ribeiro AW, Ramos DF, et al. Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene. J Clin Microbiol. 2011;49(7):2625–2630. doi:10.1128/jcm.00168-11
   PubMed Web of Science ®Google Scholar
• Ramaswamy SV, Amin AG, Göksel S, et al. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000;44(2):326–336. doi:10.1128/aac.44.2.326-336.2000
   PubMed Web of Science ®Google Scholar
• Brossier F, Sougakoff W, Bernard C, et al. Molecular analysis of the embCAB Locus and embR Gene involved in ethambutol resistance in clinical isolates of mycobacterium tuberculosis in France. Antimicrob Agents Chemother. 2015;59(8):4800–4808. doi:10.1128/aac.00150-15
   PubMed Web of Science ®Google Scholar
• Xu Y, Jia H, Huang H, Sun Z, Zhang Z. Mutations found in embCAB, embR, and ubiA genes of ethambutol-sensitive and -resistant mycobacterium tuberculosis clinical isolates from China. Biomed Res Int. 2015;2015:951706. doi:10.1155/2015/951706
   PubMed Web of Science ®Google Scholar
• Desjardins CA, Cohen KA, Munsamy V, et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat Genet. 2016;48(5):544–551. doi:10.1038/ng.3548
   PubMed Web of Science ®Google Scholar
• Belanger AE, Porter JC, Hatfull GF. Genetic analysis of peptidoglycan biosynthesis in mycobacteria: characterization of a ddlA mutant of Mycobacterium smegmatis. J Bacteriol. 2000;182(23):6854–6856. doi:10.1128/jb.182.23.6854-6856.2000
   Web of Science ®Google Scholar
• Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005;49(8):3192–3197. doi:10.1128/aac.49.8.3192-3197.2005
   PubMed Web of Science ®Google Scholar
• Maus CE, Plikaytis BB, Shinnick TM. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005;49(2):571–577. doi:10.1128/aac.49.2.571-577.2005
   PubMed Web of Science ®Google Scholar
• Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother. 2009;53(12):5064–5068. doi:10.1128/aac.00851-09
   PubMed Web of Science ®Google Scholar
• Malinga L, Brand J, Olorunju S, Stoltz A, van der Walt M. Molecular analysis of genetic mutations among cross-resistant second-line injectable drugs reveals a new resistant mutation in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 2016;85(4):433–437. doi:10.1016/j.diagmicrobio.2016.05.010
   PubMed Web of Science ®Google Scholar
• Hillemann D, Rüsch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother. 2008;52(2):800–801. doi:10.1128/aac.01189-07
   PubMed Web of Science ®Google Scholar
• Zimenkov DV, Nosova EY, Kulagina EV, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother. 2017;72(7):1901–1906. doi:10.1093/jac/dkx094
   PubMed Web of Science ®Google Scholar
• Zong Z, Jing W, Shi J, et al. Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant mycobacterium tuberculosis in China. Antimicrob Agents Chemother. 2018;62:8. doi:10.1128/aac.00165-18
   Web of Science ®Google Scholar
• Werngren J, Alm E, Mansjö M. Non-pncA gene-mutated but pyrazinamide-resistant mycobacterium tuberculosis: why is that? J Clin Microbiol. 2017;55(6):1920–1927. doi:10.1128/jcm.02532-16
   PubMed Web of Science ®Google Scholar
• Saeed DK, Shakoor S, Razzak SA, et al. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan. BMC Microbiol. 2022;22(1):62. doi:10.1186/s12866-022-02475-4
   Web of Science ®Google Scholar
• Nguyen TVA, Anthony RM, Bañuls AL, Nguyen TVA, Vu DH, Alffenaar JC. Bedaquiline resistance: its emergence, mechanism, and prevention. Clin Infect Dis. 2018;66(10):1625–1630. doi:10.1093/cid/cix992
   PubMed Web of Science ®Google Scholar
• Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60(8):4590–4599. doi:10.1128/aac.00753-16
   PubMed Web of Science ®Google Scholar
• Karmakar M, Rodrigues CHM, Holt KE, Dunstan SJ, Denholm J, Ascher DB. Empirical ways to identify novel bedaquiline resistance mutations in AtpE. PLoS One. 2019;14(5):e0217169. doi:10.1371/journal.pone.0217169
   PubMed Web of Science ®Google Scholar
• Xu J, Wang B, Hu M, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61:6. doi:10.1128/aac.00239-17
   Web of Science ®Google Scholar
• Chauhan A, Kumar M, Kumar A, Kanchan K. Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs. Life Sci. 2021;274:119301. doi:10.1016/j.lfs.2021.119301
   PubMed Web of Science ®Google Scholar
• Manjunatha UH, Boshoff H, Dowd CS, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2006;103(2):431–436. doi:10.1073/pnas.0508392103
   PubMed Web of Science ®Google Scholar
• Forouhar F, Abashidze M, Xu H, et al. Molecular insights into the biosynthesis of the F420 coenzyme. J Biol Chem. 2008;283(17):11832–11840. doi:10.1074/jbc.M710352200
   Web of Science ®Google Scholar
• Bashiri G, Rehan AM, Sreebhavan S, Baker HM, Baker EN, Squire CJ. Elongation of the Poly-γ-glutamate Tail of F420 Requires Both Domains of the F420:γ-Glutamyl Ligase (FbiB) of Mycobacterium tuberculosis. J Biol Chem. 2016;291(13):6882–6894. doi:10.1074/jbc.M115.689026
   Web of Science ®Google Scholar
• Xavier AS, Lakshmanan M. Delamanid: a new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014;5(3):222–224. doi:10.4103/0976-500x.136121
   PubMedGoogle Scholar
• Nguyen QT, Trinco G, Binda C, Mattevi A, Fraaije MW. Discovery and characterization of an F(420)-dependent glucose-6-phosphate dehydrogenase (Rh-FGD1) from Rhodococcus jostii RHA1. Appl Microbiol Biotechnol. 2017;101(7):2831–2842. doi:10.1007/s00253-016-8038-y
   Web of Science ®Google Scholar
• Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis. 2003;83(1–3):91–97. doi:10.1016/s1472-9792(02)00089-6
   PubMed Web of Science ®Google Scholar
• Grover N, Paskaleva EE, Mehta KK, Dordick JS, Kane RS. Growth inhibition of Mycobacterium smegmatis by mycobacteriophage-derived enzymes. Enzyme Microb Technol. 2014;63:1–6. doi:10.1016/j.enzmictec.2014.04.018
   Web of Science ®Google Scholar
• Liang J, Liu F, Xu P, et al. Molecular recognition of trehalose and trehalose analogues by Mycobacterium tuberculosis LpqY-SugABC. Proc Natl Acad Sci U S A. 2023;120(35):e2307625120. doi:10.1073/pnas.2307625120
   Google Scholar
• Kalscheuer R, Weinrick B, Veeraraghavan U, Besra GS, Jacobs WR. Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2010;107(50):21761–21766. doi:10.1073/pnas.1014642108
   PubMed Web of Science ®Google Scholar
• Lee JJ, Lee SK, Song N, et al. Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis. Nat Commun. 2019;10(1):2928. doi:10.1038/s41467-019-10975-7
   PubMedGoogle Scholar
• Song L, Wu X. Development of efflux pump inhibitors in antituberculosis therapy. Int J Antimicrob Agents. 2016;47(6):421–429. doi:10.1016/j.ijantimicag.2016.04.007
   PubMed Web of Science ®Google Scholar
• de Souza JVP, Murase LS, Caleffi-Ferracioli KR, et al. Isoniazid and verapamil modulatory activity and efflux pump gene expression in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2020;24(6):591–596. doi:10.5588/ijtld.19.0458
   PubMed Web of Science ®Google Scholar
• Long Y, Wang B, Xie T, et al. Overexpression of efflux pump genes is one of the mechanisms causing drug resistance in Mycobacterium tuberculosis. Microbiol Spectr. 2023:e0251023. doi:10.1128/spectrum.02510-23
   Google Scholar
• Ghajavand H, Kargarpour Kamakoli M, Khanipour S, et al. Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant Mycobacterium tuberculosis: mutations versus efflux pumps. Antimicrob Resist Infect Control. 2019;8:70. doi:10.1186/s13756-019-0516-4
   Web of Science ®Google Scholar
• Gygli SM, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017;41(3):354–373.
   PubMed Web of Science ®Google Scholar
• Slayden RA, Lee RE, Barry CE. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol Microbiol. 2000;38(3):514–525. doi:10.1046/j.1365-2958.2000.02145.x
   PubMed Web of Science ®Google Scholar
• Prasad MS, Bhole RP, Khedekar PB, Chikhale RV. Mycobacterium enoyl acyl carrier protein reductase (InhA): a key target for antitubercular drug discovery. Bioorg Chem. 2021;115:105242. doi:10.1016/j.bioorg.2021.105242
   PubMed Web of Science ®Google Scholar
• Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC. Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob Agents Chemother. 2011;55(1):291–301. doi:10.1128/aac.00558-10
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu M, Wang Y, Pang Y, Kam KM, Zhao Y. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China. Eur J Clin Microbiol Infect Dis. 2014;33(11):1959–1966. doi:10.1007/s10096-014-2144-5
   Web of Science ®Google Scholar
• Kohler N, Karakose H, Grobbel HP, et al. A single-run HPLC-MS multiplex assay for therapeutic drug monitoring of relevant first- and second-line antibiotics in the treatment of drug-resistant tuberculosis. Pharmaceutics. 2023;15(11). doi:10.3390/pharmaceutics15112543
   Web of Science ®Google Scholar
• Schami A, Islam MN, Belisle JT, Torrelles JB. Drug-resistant strains of Mycobacterium tuberculosis: cell envelope profiles and interactions with the host. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1274175
   Google Scholar
• Verma JS, Rawat D, Hasan A, et al. The use of E-test for the drug susceptibility testing of Mycobacterium tuberculosis - a solution or an illusion? Indian J Med Microbiol. 2010;28(1):30–33. doi:10.4103/0255-0857.58725
   Web of Science ®Google Scholar
• Slail MJ, Booq RY, Al-Ahmad IH, et al. Evaluation of xpert MTB/RIF ultra for the diagnosis of extrapulmonary tuberculosis: a retrospective analysis in Saudi Arabia. J Epidemiol Glob Health. 2023;13(4):782–793. doi:10.1007/s44197-023-00150-z
   Web of Science ®Google Scholar
• Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis. 2015;2(Suppl 2):S21–8. doi:10.1093/infdis/jiu803
   Google Scholar
• Denkinger CM, Kik SV, Cirillo DM, et al. Defining the needs for next generation assays for tuberculosis. J Infect Dis. 2015;2(Suppl 2):S29–38. doi:10.1093/infdis/jiu821
   Google Scholar
• Kwak M, Lee WK, Lim YJ, Lee SH, Ryoo S. Systematic review and meta-analysis of the nitrate reductase assay for drug susceptibility testing of Mycobacterium tuberculosis and the detection limits in liquid medium. J Microbiol Methods. 2017;141:1–9. doi:10.1016/j.mimet.2017.07.001
   Web of Science ®Google Scholar
• Coban AY, Deveci A, Sunter AT, Martin A. Nitrate reductase assay for rapid detection of isoniazid, rifampin, ethambutol, and streptomycin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Clin Microbiol. 2014;52(1):15–19. doi:10.1128/JCM.01990-13
   PubMed Web of Science ®Google Scholar
• Kammoun S, Smaoui S, Marouane C, Slim L, Messadi-Akrout F. Drug susceptibility testing of Mycobacterium tuberculosis by a nitrate reductase assay applied directly on microscopy-positive sputum samples. Int J Mycobacteriol. 2015;4(3):202–206. doi:10.1016/j.ijmyco.2015.04.005
   Google Scholar
• Musa HR, Ambroggi M, Souto A, Angeby KA. Drug susceptibility testing of Mycobacterium tuberculosis by a nitrate reductase assay applied directly on microscopy-positive sputum samples. J Clin Microbiol. 2005;43(7):3159–3161. doi:10.1128/jcm.43.7.3159-3161.2005
   Web of Science ®Google Scholar
• Kohli A, Bashir G, Fatima A, Jan A, Wani NU, Ahmad J. Rapid drug-susceptibility testing of Mycobacterium tuberculosis clinical isolates to first-line antitubercular drugs by nitrate reductase assay: a comparison with proportion method. Int J Mycobacteriol. 2016;5(4):469–474. doi:10.1016/j.ijmyco.2016.06.006
   Google Scholar
• Li S, Tan Y, Deng Y, et al. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: observations on surveillance data. J Infect Public Health. 2024;17(1):137–142. doi:10.1016/j.jiph.2023.11.018
   Web of Science ®Google Scholar
• L-l Z, Xia Q, Lin N, et al. Evaluation of BACTEC MGIT 960 system for the second-line drugs susceptibility testing of Mycobacterium tuberculosis in China. Journal of Microbiological Methods. 2012;91(1):212–214. doi:10.1016/j.mimet.2012.06.010
   Web of Science ®Google Scholar
• Rafael LL, Raquel MS, Rogelio FA, Miroslava FP, Alejandra-Isabel JG, Paola RS. Discordant results between genotypic and phenotypic assays (Xpert MTB/RIF vs. BACTEC MGIT 960 system) for detection of RIF-resistant Mycobacterium tuberculosis isolates in a high burden region. Infect Genet Evol. 2021;96:105142. doi:10.1016/j.meegid.2021.105142
   Web of Science ®Google Scholar
• Peng J, Yu X, Cui Z, et al. Multi-fluorescence real-time PCR assay for detection of RIF and INH resistance of M. tuberculosis. Front Microbiol. 2016;7:618. doi:10.3389/fmicb.2016.00618
   Web of Science ®Google Scholar
• Allix-Beguec C; Consortium CR, the GP. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med. 2018;379(15):1403–1415. doi:10.1056/NEJMoa1800474
   PubMed Web of Science ®Google Scholar
• Mu J, Liu Z, Zhang C, et al. Performance of the MeltPro MTB assays in the diagnosis of drug-resistant tuberculosis using formalin-fixed, paraffin-embedded tissues. Am J Clin Pathol. 2021;156(1):34–41. doi:10.1093/ajcp/aqaa203
   Web of Science ®Google Scholar
• Gupta RK, Anthwal D, Bhalla M, Tyagi JS, Choudhary S, Haldar S. Direct detection of fluoroquinolone resistance in sputum samples from tuberculosis patients by high resolution melt curve analysis. Curr Microbiol. 2023;81(1):27. doi:10.1007/s00284-023-03519-2
   Web of Science ®Google Scholar
• Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6(9):1067–1082. doi:10.2217/fmb.11.84
   PubMed Web of Science ®Google Scholar
• Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;2014(1):Cd009593. doi:10.1002/14651858.CD009593.pub3
   PubMed Web of Science ®Google Scholar
• Kolia-Diafouka P, Carrère-Kremer S, Lounnas M, et al. Detection of Mycobacterium tuberculosis in paucibacillary sputum: performances of the Xpert MTB/RIF ultra compared to the Xpert MTB/RIF, and IS6110 PCR. Diagn Microbiol Infect Dis. 2019;94(4):365–370. doi:10.1016/j.diagmicrobio.2019.02.008
   PubMed Web of Science ®Google Scholar
• Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A. 1989;86(16):6230–6234. doi:10.1073/pnas.86.16.6230
   PubMed Web of Science ®Google Scholar
• Lin M, Chen Y-W, Li Y-R, et al. Systematic evaluation of line probe assays for the diagnosis of tuberculosis and drug-resistant tuberculosis. Clinica Chimica Acta. 2022;533:183–218. doi:10.1016/j.cca.2022.06.020
   Web of Science ®Google Scholar
• Aricha SA, Kingwara L, Mwirigi NW, et al. Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya. BMC Infect Dis. 2019;19(1):852. doi:10.1186/s12879-019-4470-9
   Web of Science ®Google Scholar
• Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2017;49(1). doi:10.1183/13993003.01075-2016
   Web of Science ®Google Scholar
• Guo Q, Yu Y, Zhu YL, et al. Rapid detection of rifampin-resistant clinical isolates of Mycobacterium tuberculosis by reverse dot blot hybridization. Biomed Environ Sci. 2015;28(1):25–35. doi:10.3967/bes2015.003
   Web of Science ®Google Scholar
• Hofmann-Thiel S, van Ingen J, Feldmann K, et al. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J. 2009;33(2):368–374. doi:10.1183/09031936.00089808
   Web of Science ®Google Scholar
• Hu S, Li G, Li H, et al. Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis. J Clin Microbiol. 2014;52(5):1644–1652. doi:10.1128/jcm.03395-13
   Web of Science ®Google Scholar
• Zheng Y, Xia H, Bao X, Zhao B, He P, Zhao Y. Highly sensitive detection of isoniazid heteroresistance in mycobacterium tuberculosis by droplet digital PCR. Infect Drug Resist. 2022;15:6245–6254. doi:10.2147/idr.S381097
   Web of Science ®Google Scholar
• Pholwat S, Stroup S, Foongladda S, Houpt E. Digital PCR to detect and quantify heteroresistance in drug resistant Mycobacterium tuberculosis. PLoS One. 2013;8(2):e57238. doi:10.1371/journal.pone.0057238
   Web of Science ®Google Scholar
• Zhang S, Chen X, Lin Z, et al. Quantification of isoniazid-heteroresistant mycobacterium tuberculosis using droplet digital PCR. J Clin Microbiol. 2023;61(6):e0188422. doi:10.1128/jcm.01884-22
   Web of Science ®Google Scholar
• Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection. Annu Rev Pathol. 2019;14:319–338. doi:10.1146/annurev-pathmechdis-012418-012751
   PubMed Web of Science ®Google Scholar
• Cason C, D’Accolti M, Soffritti I, Mazzacane S, Comar M, Caselli E. Next-generation sequencing and PCR technologies in monitoring the hospital microbiome and its drug resistance. Front Microbiol. 2022;13:969863. doi:10.3389/fmicb.2022.969863
   Google Scholar
• Zhang G, Zhang H, Hu X, et al. Clinical application value of metagenomic next-generation sequencing in the diagnosis of spinal infections and its impact on clinical outcomes. Front Cell Infect Microbiol. 2023;13:1076525. doi:10.3389/fcimb.2023.1076525
   PubMedGoogle Scholar
• Xiang ZB, Leng EL, Cao WF, et al. A systematic review and meta-analysis of the diagnostic accuracy of metagenomic next-generation sequencing for diagnosing tuberculous meningitis. Front Immunol. 2023;14:1223675. doi:10.3389/fimmu.2023.1223675
   Web of Science ®Google Scholar
• Cabibbe AM, Spitaleri A, Battaglia S, et al. Application of targeted next-generation sequencing assay on a portable sequencing platform for culture-free detection of drug-resistant tuberculosis from clinical samples. J Clin Microbiol. 2020;58(10). doi:10.1128/JCM.00632-20
   Web of Science ®Google Scholar
• Zhang G, Zhang H, Zhang Y, Hu X, Tang M, Gao Q. Targeted next-generation sequencing technology showed great potential in identifying spinal tuberculosis and predicting the drug resistance. J Infect. 2023;87(6):e110–e112. doi:10.1016/j.jinf.2023.10.018
   Web of Science ®Google Scholar
• Lin Q, Yao Y, Li X, et al. The application of nanopore targeted sequencing for pathogen diagnosis in bronchoalveolar lavage fluid of patients with pneumonia: a prospective multicenter study. Infect Dis. 2024;56(2):128–137. doi:10.1080/23744235.2023.2276785
   PubMed Web of Science ®Google Scholar
• Sun X, Song J, Leng X, et al. A preliminary evaluation of targeted nanopore sequencing technology for the detection of Mycobacterium tuberculosis in bronchoalveolar lavage fluid specimens. Front Cell Infect Microbiol. 2023;13:1107990. doi:10.3389/fcimb.2023.1107990
   PubMed Web of Science ®Google Scholar
• Dippenaar A, Goossens SN, Grobbelaar M, et al. Nanopore sequencing for mycobacterium tuberculosis: a critical review of the literature, new developments, and future opportunities. J Clin Microbiol. 2022;60(1):e0064621. doi:10.1128/JCM.00646-21
   PubMed Web of Science ®Google Scholar
• Wu W, Cheng P, Lyu J, Zhang Z, Xu J. Tag Array gene chip rapid diagnosis anti-tuberculosis drug resistance in pulmonary tuberculosis -a feasibility study. Tuberculosis. 2018;110:96–103. doi:10.1016/j.tube.2018.03.010
   Web of Science ®Google Scholar
• Torres JN, Paul LV, Rodwell TC, et al. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect. 2015;4(7):e42. doi:10.1038/emi.2015.42
   PubMedGoogle Scholar
• Feng G, Han W, Shi J, Xia R, Xu J. Analysis of the application of a gene chip method for detecting Mycobacterium tuberculosis drug resistance in clinical specimens: a retrospective study. Sci Rep. 2021;11(1):17951. doi:10.1038/s41598-021-97559-y
   Web of Science ®Google Scholar
• Parveen S, Shen J, Lun S, et al. Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis. Nat Commun. 2023;14(1):7427. doi:10.1038/s41467-023-43304-0
   PubMedGoogle Scholar
• Chaiyachat P, Kaewseekhao B, Chaiprasert A, et al. Metabolomic analysis of Mycobacterium tuberculosis reveals metabolic profiles for identification of drug-resistant tuberculosis. Sci Rep. 2023;13(1):8655. doi:10.1038/s41598-023-35882-2
   Web of Science ®Google Scholar
• Janssen EM, Dy SM, Meara AS, Kneuertz PJ, Presley CJ, Bridges JFP. Analysis of patient preferences in lung cancer - estimating acceptable tradeoffs between treatment benefit and side effects. Patient Prefer Adherence. 2020;14:927–937. doi:10.2147/ppa.S235430
   PubMed Web of Science ®Google Scholar
• Wang L, Ying R, Liu Y, Sun Q, Sha W. Metabolic profiles of clinical isolates of drug-susceptible and multidrug-resistant mycobacterium tuberculosis: a metabolomics-based study. Infect Drug Resist. 2023;16:2667–2680. doi:10.2147/IDR.S405987
   Web of Science ®Google Scholar
• Xu G, Liu H, Jia X, Wang X, Xu P. Mechanisms and detection methods of Mycobacterium tuberculosis rifampicin resistance: the phenomenon of drug resistance is complex. Tuberculosis. 2021;128:102083. doi:10.1016/j.tube.2021.102083
   Web of Science ®Google Scholar
• Weerakoon KG, McManus DP. Cell-free DNA as a diagnostic tool for human parasitic infections. Trends Parasitol. 2016;32(5):378–391. doi:10.1016/j.pt.2016.01.006
   PubMed Web of Science ®Google Scholar
• Traver S, Assou S, Scalici E, et al. Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy. Hum Reprod Update. 2014;20(6):905–923. doi:10.1093/humupd/dmu031
   PubMed Web of Science ®Google Scholar
• Aucamp J, Bronkhorst AJ, Badenhorst CPS, Pretorius PJ. The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. Biol Rev Camb Philos Soc. 2018;93(3):1649–1683. doi:10.1111/brv.12413
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73(4):1907–1916. doi:10.1128/iai.73.4.1907-1916.2005
   PubMed Web of Science ®Google Scholar
• Pan SW, Su WJ, Chan YJ, Chuang FY, Feng JY, Chen YM. Mycobacterium tuberculosis-derived circulating cell-free DNA in patients with pulmonary tuberculosis and persons with latent tuberculosis infection. PLoS One. 2021;16(6):e0253879. doi:10.1371/journal.pone.0253879
   Web of Science ®Google Scholar
• Labugger I, Heyckendorf J, Dees S, et al. Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring. Infection. 2017;45(3):269–276. doi:10.1007/s15010-016-0955-2
   Web of Science ®Google Scholar
• Casadevall A, Fang FC. The intracellular pathogen concept. Mol Microbiol. 2020;113(3):541–545. doi:10.1111/mmi.14421
   Web of Science ®Google Scholar
• Wu X, Liang R, Xiao Y, et al. Application of targeted next generation sequencing technology in the diagnosis of Mycobacterium Tuberculosis and first line drugs resistance directly from cell-free DNA of bronchoalveolar lavage fluid. J Infect. 2023;86(4):399–401. doi:10.1016/j.jinf.2023.01.031
   Web of Science ®Google Scholar
• Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709–1712. doi:10.1126/science.1138140
   PubMed Web of Science ®Google Scholar
• Liu P, Wang X, Liang J, et al. A recombinase polymerase amplification-coupled Cas12a mutant-based module for efficient detection of streptomycin-resistant mutations in mycobacterium tuberculosis. Front Microbiol. 2021;12:796916. doi:10.3389/fmicb.2021.796916
   Web of Science ®Google Scholar
• Bai X, Gao P, Qian K, et al. A highly sensitive and specific detection method for mycobacterium tuberculosis fluoroquinolone resistance mutations utilizing the CRISPR-Cas13a system. Front Microbiol. 2022;13:847373. doi:10.3389/fmicb.2022.847373
   Google Scholar
• Li S, Poulton NC, Chang JS, et al. CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis. Nat Microbiol. 2022;7(6):766–779. doi:10.1038/s41564-022-01130-y
   Web of Science ®Google Scholar
• Yan MY, Zheng D, Li SS, et al. Application of combined CRISPR screening for genetic and chemical-genetic interaction profiling in Mycobacterium tuberculosis. Sci Adv. 2022;8(47):eadd5907. doi:10.1126/sciadv.add5907
   Web of Science ®Google Scholar
• Samukawa N, Yamaguchi T, Ozeki Y, et al. An efficient CRISPR interference-based prediction method for synergistic/additive effects of novel combinations of anti-tuberculosis drugs. Microbiology. 2022;168:12. doi:10.1099/mic.0.001285
   Web of Science ®Google Scholar
• Tram TTB, Ha VTN, Trieu LPT, et al. FLASH-TB: an application of next-generation CRISPR to detect drug resistant tuberculosis from direct sputum. J Clin Microbiol. 2023;61(4):e0163422. doi:10.1128/jcm.01634-22
   Web of Science ®Google Scholar
• Shi J, He G, Ning H, et al. Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. Tuberculosis. 2022;135:102209. doi:10.1016/j.tube.2022.102209
   PubMed Web of Science ®Google Scholar
• Lavigne JP, Espinal P, Dunyach-Remy C, Messad N, Pantel A, Sotto A. Mass spectrometry: a revolution in clinical microbiology? Clin Chem Lab Med. 2013;51(2):257–270. doi:10.1515/cclm-2012-0291
   PubMed Web of Science ®Google Scholar
• Sauer S, Kliem M. Mass spectrometry tools for the classification and identification of bacteria. Nat Rev Microbiol. 2010;8(1):74–82. doi:10.1038/nrmicro2243
   PubMed Web of Science ®Google Scholar
• Strola SA, Baritaux JC, Schultz E, et al. Single bacteria identification by Raman spectroscopy. J Biomed Opt. 2014;19(11):111610. doi:10.1117/1.JBO.19.11.111610
   PubMed Web of Science ®Google Scholar
• Tang JW, Liu QH, Yin XC, et al. Comparative analysis of machine learning algorithms on surface enhanced raman spectra of clinical staphylococcus species. Front Microbiol. 2021;12:696921. doi:10.3389/fmicb.2021.696921
   Web of Science ®Google Scholar
• Perumal J, Dinish US, Bendt AK, et al. Identification of mycolic acid forms using surface-enhanced Raman scattering as a fast detection method for tuberculosis. Int J Nanomedicine. 2018;13:6029–6038. doi:10.2147/ijn.S171400
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang XD, Tang JW, et al. Machine learning analysis of SERS fingerprinting for the rapid determination of Mycobacterium tuberculosis infection and drug resistance. Comput Struct Biotechnol J. 2022;20:5364–5377. doi:10.1016/j.csbj.2022.09.031
   Web of Science ®Google Scholar
• Lyu JW, Zhang XD, Tang JW, et al. Rapid prediction of multidrug-resistant Klebsiella pneumoniae through deep learning analysis of SERS spectra. Microbiol Spectr. 2023;11(2):e0412622. doi:10.1128/spectrum.04126-22
   Web of Science ®Google Scholar
• Mathew A, Amudha P, Sivakumari S. Deep learning techniques: an overview. In: Hassanien AE, Bhatnagar R, Darwish A, editors. Advanced Machine Learning Technologies and Applications. Singapore: Springer Singapore; 2021:599–608.
   Google Scholar
• Pavšič J, Žel J, Milavec M. Digital PCR for direct quantification of viruses without DNA extraction. Anal Bioanal Chem. 2016;408(1):67–75. doi:10.1007/s00216-015-9109-0
   PubMed Web of Science ®Google Scholar
• Trypsteen W, Vynck M, De Neve J, et al. ddpcRquant: threshold determination for single channel droplet digital PCR experiments. Anal Bioanal Chem. 2015;407(19):5827–5834. doi:10.1007/s00216-015-8773-4
   PubMed Web of Science ®Google Scholar
• Bosman KJ, Nijhuis M, van Ham PM, et al. Comparison of digital PCR platforms and semi-nested qPCR as a tool to determine the size of the HIV reservoir. Sci Rep. 2015;5:13811. doi:10.1038/srep13811
   PubMed Web of Science ®Google Scholar